# A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

> **NCT04257032** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin + BI 1323495
- **DRUG:** Dabigatran etexilate
- **DRUG:** Dabigatran etexilate + BI 1323495

## Key facts

- **NCT ID:** NCT04257032
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-13
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-09-23
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04257032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04257032, "A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04257032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*